IRIDEX Corporation (IRIX)
NASDAQ: IRIX · Real-Time Price · USD
1.000
+0.010 (1.01%)
Apr 1, 2025, 10:01 AM EDT - Market open
IRIDEX Revenue
In the year 2024, IRIDEX had annual revenue of $48.67M, down -6.17%. IRIDEX had revenue of $12.70M in the quarter ending December 28, 2024, with 1.91% growth.
Revenue (ttm)
$48.67M
Revenue Growth
-6.17%
P/S Ratio
0.33
Revenue / Employee
$438,459
Employees
111
Market Cap
16.79M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 28, 2024 | 48.67M | -3.20M | -6.17% |
Dec 30, 2023 | 51.87M | -5.10M | -8.96% |
Dec 31, 2022 | 56.97M | 3.07M | 5.69% |
Jan 1, 2022 | 53.90M | 17.56M | 48.30% |
Jan 2, 2021 | 36.35M | -7.10M | -16.34% |
Dec 28, 2019 | Pro | Pro | Pro |
Dec 29, 2018 | Pro | Pro | Pro |
Dec 30, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Jan 2, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
IRIX News
- 4 days ago - IRIDEX Corporation (IRIX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Iridex Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 13 days ago - Iridex Announces Strategic Investment in the Company - GlobeNewsWire
- 18 days ago - Iridex Comments on Recent Stock Price Volatility - GlobeNewsWire
- 18 days ago - Iridex to Report Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025 - GlobeNewsWire
- 3 months ago - Iridex Announces Milestone Five-Year Study Confirms the Long-Term Effectiveness and Safety of MicroPulse Transscleral Cyclophotocoagulation for Glaucoma Management - GlobeNewsWire
- 4 months ago - Iridex Comments on Changing Glaucoma Reimbursement Landscape - GlobeNewsWire
- 4 months ago - IRIDEX Corporation (IRIX) Q3 2024 Earnings Call Transcript - Seeking Alpha